⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 4, 2024Open Access

Supplementary Figure 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment

David A. Knorr Lucas Blanchard Rom S. Leidner Shawn M. Jensen Ryan Meng Andrew Jones Carmen Ballesteros‐Merino R. Bryan Bell Maria Baez Alessandra Marino David E. Sprott Carlo Bifulco Brian Piening Rony Dahan Juan C. Osorio Bernard A. Fox Jeffrey V. Ravetch

View Full Paper

Ask AI

Bookmark

Share

Abstract

Biological activity of the anti-murine CD4 antibody GK1.5 harboring a human IgG1 Fc

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Knorr et al. (2024) studied this question.

synapsesocial.com/papers/68e75dd0b6db6435876d4b63 https://doi.org/10.1158/2326-6066.25338241

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 2 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment2024
2Supplementary Figure 4 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment2024
3Supplementary Figure 4 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment2024
4Supplementary Figure 3 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment2024
5Supplementary Figure 3 from FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment2024